AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
MetabolomeMetabolomicsGas Chromatography-Mass SpectrometryMass SpectrometryMetabolismPrincipal Component AnalysisChromatography, LiquidAdrenogenital SyndromeMetabolic Networks and PathwaysSteroid Metabolism, Inborn ErrorsSecondary MetabolismVolatile Organic CompoundsElectrophoresis, CapillaryProteomeMagnetic Resonance SpectroscopySystems BiologyCarbonEricaceaeModels, BiologicalTranscriptomeGene Expression ProfilingGlycolysisGene Expression Regulation, PlantMetagenomeSpectrometry, Mass, Electrospray IonizationArabidopsisBiosynthetic PathwaysPentose Phosphate PathwaySolid Phase MicroextractionTandem Mass SpectrometryDatabases, FactualAmino AcidsPlant LeavesLeast-Squares Analysis

CSF metabolic and proteomic profiles in patients prodromal for psychosis. (1/1048)

BACKGROUND: The initial prodromal state of psychosis (IPS) is defined as an early disease stage prior to the onset of overt psychosis characterized by sub-threshold or more unspecific psychiatric symptoms. Little is known regarding the biochemical changes during this period. METHODOLOGY/PRINCIPAL FINDINGS: We investigated the metabolic/proteomic profiles of cerebrospinal fluid (CSF) of first-onset drug naive paranoid schizophrenia patients (n = 54) and individuals presenting with initial prodromal symptoms (n = 24), alongside healthy volunteers (n = 70) using proton nuclear magnetic resonance ((1)H-NMR) spectroscopy and surface enhanced laser desorption ionization (SELDI) mass spectrometry, respectively. Partial least square discriminant analysis (PLS-DA) showed that 36%/29% of IPS patients displayed proteomic/metabolic profiles characteristic of first-onset, drug naive schizophrenia, i.e., changes in levels of glucose and lactate as well as changes in a VGF-derived peptide (VGF23-62) and transthyretin protein concentrations. However, only 29% (n = 7) of the investigated IPS patients (who to date have been followed up for up to three years) have so far received a diagnosis of schizophrenia. The presence of biochemical alterations in the IPS group did not correlate with the risk to develop schizophrenia. CONCLUSIONS/SIGNIFICANCE: Our results imply that schizophrenia-related biochemical disease processes can be traced in CSF of prodromal patients. However, the biochemical disturbances identified in IPS patients, at least when measured at a single time point, may not be sufficient to predict clinical outcome.  (+info)

Metabolite quantification and high-field MRS in breast cancer. (2/1048)

In vivo 1H MRS is rapidly developing as a clinical tool for diagnosing and characterizing breast cancers. Many in vivo and in vitro experiments have demonstrated that alterations in concentrations of choline-containing metabolites are associated with malignant transformation. In recent years, considerable efforts have been made to evaluate the role of 1H MRS measurements of total choline-containing compounds in the management of patients with breast cancer. Current technological developments, including the use of high-field MR scanners and quantitative spectroscopic analysis methods, promise to increase the sensitivity and accuracy of breast MRS. This article reviews the literature describing in vivo MRS in breast cancer, with an emphasis on the development of high-field MR scanning and quantitative methods. Potential applications of these technologies for diagnosing suspicious lesions and monitoring response to chemotherapy are discussed.  (+info)

Perceiving molecular evolution processes in Escherichia coli by comprehensive metabolite and gene expression profiling. (3/1048)

 (+info)

Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. (4/1048)

 (+info)

Metabolic profiling of an Echinostoma caproni infection in the mouse for biomarker discovery. (5/1048)

 (+info)

Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. (6/1048)

 (+info)

Gene module level analysis: identification to networks and dynamics. (7/1048)

 (+info)

Genome-scale model for Clostridium acetobutylicum: Part II. Development of specific proton flux states and numerically determined sub-systems. (8/1048)

 (+info)